DDInter699 DDInter899
Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Etodolac {u} (Compound) binds {v} (Gene) CYP2C9
Etodolac {u} (Compound) upregulates {v} (Gene) SERPINA3
Etodolac {u} (Compound) palliates {v} (Disease) osteoarthritis
Etodolac {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Etodolac {u} (Compound) downregulates {v} (Gene) RAI14
Etodolac {u} (Compound) causes {v} (Side Effect) Rhinitis
Etodolac {u} may cause a minor interaction that can limit clinical effects when taken with {v} Linaclotide
Etodolac {u} may cause a minor interaction that can limit clinical effects when taken with {v} Nizatidine
Etodolac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anistreplase
Etodolac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sodium sulfate
Etodolac (Compound) binds CYP2C9 (Gene)
Etodolac (Compound) upregulates SERPINA3 (Gene)
Etodolac (Compound) palliates osteoarthritis (Disease)
Etodolac (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class)
Etodolac (Compound) downregulates RAI14 (Gene)
Etodolac (Compound) causes Rhinitis (Side Effect)
Etodolac may cause a minor interaction that can limit clinical effects when taken with Linaclotide
Etodolac may cause a minor interaction that can limit clinical effects when taken with Nizatidine
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Anistreplase
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate